Public market insider buying at Profound Medical (T:PRN)

Arun Menawat, CEO and Director, acquired 13,000 Common Shares on a direct ownership basis at a price of $7.807USD on December 20th, 2022. This represents a $138,234 investment into the company's shares and an account share holdings change of 3.2%.

Profound Medical is in the Advanced Medical Equipment & Technology Sub Industry Group under the Healthcare Sector.

Profound Medical Corp. is a Canada-based commercial-stage medical device company. The Company is focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare systems existing imaging infrastructure. The Company is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient's natural functional abilities. The Company is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.